4//SEC Filing
Voytas Daniel F 4
Accession 0001127602-19-003835
CIK 0001705843other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 5:41 PM ET
Size
18.7 KB
Accession
0001127602-19-003835
Insider Transaction Report
Form 4
Calyxt, Inc.CLXT
Voytas Daniel F
Chief Science Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2019-01-31−4,083→ 8,170 totalExercise: $3.71Exp: 2024-12-03→ Common Stock (4,083 underlying) - Exercise/Conversion
Common Stock
2019-01-31$3.71/sh+4,083$15,165→ 97,065 total - Sale
Common Stock
2019-01-31$13.00/sh−4,083$53,079→ 92,982 total - Sale
Common Stock
2019-02-01$13.00/sh−4,087$53,131→ 92,982 total - Exercise/Conversion
Common Stock
2019-02-01$3.71/sh+4,087$15,180→ 97,069 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-02-01−4,087→ 4,083 totalExercise: $3.71Exp: 2024-12-03→ Common Stock (4,087 underlying)
Footnotes (3)
- [F1]Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.
- [F3]The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014 and vested 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vested quarterly in equal installments thereafter, 15% of which vested immediately on July 25, 2017 when Calyxt, Inc. underwent its initial public offering.
Documents
Issuer
Calyxt, Inc.
CIK 0001705843
Entity typeother
Related Parties
1- filerCIK 0001712191
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 5:41 PM ET
- Size
- 18.7 KB